MCID: HYP030
MIFTS: 40

Hypoactive Sexual Desire Disorder

Categories: Mental diseases

Aliases & Classifications for Hypoactive Sexual Desire Disorder

MalaCards integrated aliases for Hypoactive Sexual Desire Disorder:

Name: Hypoactive Sexual Desire Disorder 12 76 15 73
Sexual Dysfunctions, Psychological 44
Lack or Loss of Sexual Desire 12

Classifications:



External Ids:

Disease Ontology 12 DOID:13868
ICD10 33 F52.0
ICD9CM 35 302.71
MeSH 44 D020018
NCIt 50 C94337
SNOMED-CT 68 78889008
UMLS 73 C0020594

Summaries for Hypoactive Sexual Desire Disorder

MalaCards based summary : Hypoactive Sexual Desire Disorder, also known as sexual dysfunctions, psychological, is related to depression and breast cancer. An important gene associated with Hypoactive Sexual Desire Disorder is CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1), and among its related pathways/superpathways are Monoamine GPCRs and Serotonergic synapse. The drugs Testosterone undecanoate and Testosterone have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and prostate, and related phenotypes are Decreased viability after Maraba virus infection and Decreased viability after Maraba virus infection

Wikipedia : 76 Hypoactive sexual desire disorder (HSDD) or inhibited sexual desire (ISD) is considered a sexual... more...

Related Diseases for Hypoactive Sexual Desire Disorder

Diseases related to Hypoactive Sexual Desire Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 43)
# Related Disease Score Top Affiliating Genes
1 depression 30.6 HTR1A HTR2A
2 breast cancer 10.2
3 aging 10.2
4 inhibited female orgasm 10.2
5 schizoid personality disorder 10.1 HTR1A HTR2A
6 personality disorder 10.1 HTR1A HTR2A
7 substance-induced psychosis 10.1 HTR1A HTR2A
8 periodic limb movement disorder 10.1 HTR1A HTR2A
9 drug-induced mental disorder 10.1 HTR1A HTR2A
10 drug psychosis 10.1 HTR1A HTR2A
11 borderline personality disorder 10.1 HTR1A HTR2A
12 serotonin syndrome 10.1 HTR1A HTR2A
13 bipolar i disorder 10.1 HTR1A HTR2A
14 androgen insensitivity, partial 10.1 CYP19A1 SHBG
15 estrogen excess 10.1 CYP19A1 SHBG
16 alopecia, androgenetic, 1 10.1 CYP19A1 SHBG
17 mental depression 10.1 HTR1A HTR2A
18 androgenic alopecia 10.1 CYP19A1 SHBG
19 complete androgen insensitivity syndrome 10.1 CYP19A1 SHBG
20 sex differentiation disease 10.0 CYP19A1 SHBG
21 sexual disorder 10.0 HTR1A SHBG
22 endogenous depression 10.0 HTR1A HTR2A
23 gynecomastia 10.0 CYP19A1 SHBG
24 generalized anxiety disorder 10.0 HTR1A HTR2A
25 anxiety 10.0 HTR1A HTR2A
26 stuttering 10.0 CYP19A1 SHBG
27 anovulation 10.0 CYP19A1 SHBG
28 chronic fatigue syndrome 10.0 HTR1A HTR2A
29 hyperandrogenism 10.0 CYP19A1 SHBG
30 female reproductive system disease 10.0 CYP19A1 SHBG
31 reproductive system disease 10.0 CYP19A1 SHBG
32 gonadal disease 10.0 CYP19A1 SHBG
33 disease of mental health 10.0 HTR1A HTR2A
34 cryptorchidism, unilateral or bilateral 10.0 CYP19A1 SHBG
35 mood disorder 10.0 HTR1A HTR2A
36 premature ovarian failure 1 10.0 CYP19A1 SHBG
37 psychotic disorder 10.0 HTR1A HTR2A
38 polycystic ovary syndrome 9.9 CYP19A1 SHBG
39 panic disorder 9.9 HTR1A HTR2A
40 obsessive-compulsive disorder 9.9 HTR1A HTR2A
41 psychosexual disorder 9.9 HTR1A HTR2A SHBG
42 bipolar disorder 9.8 HTR1A HTR2A SHBG
43 ovarian disease 9.8 CYP19A1 SHBG

Graphical network of the top 20 diseases related to Hypoactive Sexual Desire Disorder:



Diseases related to Hypoactive Sexual Desire Disorder

Symptoms & Phenotypes for Hypoactive Sexual Desire Disorder

GenomeRNAi Phenotypes related to Hypoactive Sexual Desire Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability after Maraba virus infection GR00252-A-1 9.28 CYP19A1 HTR2A
2 Decreased viability after Maraba virus infection GR00252-A-2 9.28 AP1G1 CYP19A1 SHBG
3 Decreased viability after Maraba virus infection GR00252-A-3 9.28 AP1G1 CYP19A1 HTR2A SHBG

Drugs & Therapeutics for Hypoactive Sexual Desire Disorder

Drugs for Hypoactive Sexual Desire Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 5949-44-0
2
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 58-22-0 6013
3
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2,Phase 1 315-37-7 9416
4
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1 58-18-4 6010
5
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
6 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 insulin Phase 4
8 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Androgens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Testosterone 17 beta-cypionate Phase 4,Phase 3,Phase 2,Phase 1
11 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
12 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Insulin, Globin Zinc Phase 4
14 Anabolic Agents Phase 4,Phase 3,Phase 2,Phase 1
15 Tribulus Phase 4
16 Estrogens Phase 4,Phase 3,Phase 1,Not Applicable
17 Progestins Phase 4
18 Contraceptives, Oral Phase 4
19 Contraceptive Agents Phase 4,Not Applicable
20 Contraceptives, Oral, Combined Phase 4
21
Dopamine Approved Phase 2, Phase 3,Phase 1 51-61-6, 62-31-7 681
22
Bupropion Approved Phase 2, Phase 3,Phase 1 34841-39-9, 34911-55-2 444
23
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3,Not Applicable 53-43-0 5881
24 DHEA (Dehydroepiandrosterone) Phase 3,Not Applicable
25 Adjuvants, Immunologic Phase 3,Not Applicable
26 Immunologic Factors Phase 3,Not Applicable
27 beta-endorphin Phase 3
28 alpha-MSH Phase 3,Phase 2 581-05-5
29 Melanocyte-Stimulating Hormones Phase 3
30 Adrenocorticotropic Hormone Phase 3
31 Psychotropic Drugs Phase 2, Phase 3,Phase 1
32 Antidepressive Agents Phase 2, Phase 3,Phase 1
33 Antidepressive Agents, Second-Generation Phase 2, Phase 3,Phase 1
34 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3,Phase 1
35 Dopamine Uptake Inhibitors Phase 2, Phase 3,Phase 1
36 Neurotransmitter Uptake Inhibitors Phase 2, Phase 3,Phase 1
37 Neurotransmitter Agents Phase 2, Phase 3,Phase 1
38 Dopamine Agents Phase 2, Phase 3,Phase 1
39 Cytochrome P-450 CYP2D6 Inhibitors Phase 2, Phase 3,Phase 1
40
Buspirone Approved, Investigational Phase 2 36505-84-7 2477
41
Trazodone Approved, Investigational Phase 1, Phase 2 19794-93-5 5533
42
Paroxetine Approved, Investigational Phase 2 61869-08-7 43815
43
Sertraline Approved Phase 2 79617-96-2 68617
44
Fluoxetine Approved, Vet_approved Phase 2 54910-89-3 3386
45
Ethanol Approved Phase 2 64-17-5 702
46
Methadone Approved Phase 2 76-99-3 4095
47
Guaifenesin Approved, Investigational, Vet_approved Phase 2 93-14-1 3516
48
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
49 Anti-Anxiety Agents Phase 2
50 Central Nervous System Depressants Phase 2

Interventional clinical trials:

(show top 50) (show all 61)
# Name Status NCT ID Phase Drugs
1 Testosterone Patch's Effects on the Cardiovascular System and Libido Unknown status NCT01208038 Phase 4 Intrinsa Transdermal testosterone patch
2 Effects of Tribulus Terrestris in Postmenopausal Women With Hypoactive Sexual Desire Disorder Completed NCT01975649 Phase 4 Tribulus Terrestris
3 Effects of Tribulus Terrestris in Women With Hypoactive Sexual Desire Disorder Completed NCT01971099 Phase 4 tribulus terrestris
4 Role of Progesterone in Hypoactive Sexual Desire Disorder in Menopausal Women Recruiting NCT02968342 Phase 4
5 Oral Contraceptive Therapy and Sexuality Recruiting NCT02613039 Phase 4 Combined Estrogen-Progestin Oral Contraceptives
6 Flibanserin (Addyi®) vs. Flibanserin and Sex Therapy Active, not recruiting NCT02714049 Phase 4 flibanserin
7 Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) Completed NCT01235754 Phase 3 transdermal testosterone gel 1%;placebo gel
8 Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women Completed NCT00612742 Phase 3 testosterone gel;placebo gel
9 Testosterone in Female Hypoactive Sexual Desire Disorder Completed NCT00140153 Phase 3 testosterone gel (Androgel)
10 Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women Completed NCT00657501 Phase 3 testosterone gel;placebo gel
11 Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women Completed NCT00613002 Phase 3 testosterone gel;placebo gel
12 Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women Completed NCT00467259 Phase 3 Testosterone Transdermal System;Placebo patch
13 Testosterone Therapy in Naturally Menopausal Women With Low Sexual Desire Receiving Transdermal Estrogen Completed NCT00384046 Phase 3 Testosterone;Placebo
14 Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder Completed NCT00996164 Phase 3 Flibanserin;Placebo
15 24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder Completed NCT00360529 Phase 3 flibanserin
16 A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension Completed NCT02338960 Phase 3 Bremelanotide;Placebo
17 A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension Completed NCT02333071 Phase 3 bremelanotide
18 Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido Completed NCT00338312 Phase 3 Testosterone Transdermal System;Placebo patch
19 Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido Completed NCT00331214 Phase 3 Testosterone Transdermal System;placebo patch
20 Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido Completed NCT00331123 Phase 3 Testosterone Transdermal System;Placebo
21 Study to Assess the Efficacy/Safety of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido Completed NCT00349791 Phase 3 Testosterone Transdermal System;Placebo patch
22 Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women Completed NCT00996372 Phase 3 flibanserin;placebo
23 Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder Completed NCT00360555 Phase 3 flibanserin;flibanserin 50mg;flibanserin 100mg;placebo
24 Flibanserin Versus Placebo in Premenopausal Women With HSDD Completed NCT00491829 Phase 3 50 mg qhs;100 mg;placebo
25 Study of Transdermal Testosterone Patches in Menopausal Women With Low Libido Completed NCT00131495 Phase 3 Testosterone (transdermal patches);Placebo patch
26 Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder Completed NCT00601367 Phase 3 flibanserin flexible dose
27 Female Orgasmic Disorder (FOD) and Wellbutrin XL Completed NCT00248209 Phase 2, Phase 3 Wellbutrin XL
28 6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA Completed NCT00360243 Phase 3 flibanserin;flibanserin;flibanserin;placebo
29 Zestra in Women With Mixed Sexual Dysfunction Completed NCT00118495 Phase 3 Non-prescription Zestra(TM): patented formulation
30 Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study Recruiting NCT03619005 Phase 3 Placebo Vaginal Insert;Prasterone 6.5 mg (0.50%) Vaginal Insert
31 BP101 for Adults With Female Sexual Dysfunction Recruiting NCT03463707 Phase 3 BP101;Placebo
32 Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) Active, not recruiting NCT03287232 Phase 3 Placebo Vaginal Insert;Prasterone 6.5 mg (0.50%) Vaginal Insert
33 Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America Terminated NCT01057901 Phase 3 Flibanserin;Placebo
34 A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Terminated NCT01103362 Phase 3 flibanserin
35 A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD). Terminated NCT00441558 Phase 3 Flibanserin
36 Lybridos in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Due to Maladaptive Activation of Sexual Inhibitory Systems Completed NCT01743235 Phase 2 Placebo;Testosterone;Buspirone hydrochloride
37 Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder Completed NCT02101203 Phase 2 Placebo;0.5 mgTestosterone + 10 mg Buspirone
38 Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder Completed NCT01382719 Phase 2 bremelanotide
39 Phase 1b/2a Unblinded Study of Responses in Premenopausal Women With HSDD to Lorexys Evaluating Efficacy and Safety Completed NCT01857596 Phase 1, Phase 2 bupropion, Lorexys low-dose, Lorexys moderate-dose
40 The Effect of Individualised Homeopathic Treatment on Low Sexual Desire in Perimenopause Completed NCT02419209 Phase 2
41 Lybrido for Female Sexual Dysfunction Completed NCT01432665 Phase 2 Placebo;Sildenafil;Testosterone
42 Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire Completed NCT03080298 Phase 2 BP101;Placebo
43 Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction Completed NCT00034021 Phase 2 Ginkgo Biloba
44 Safety Study of Transdermal Testosterone for Low Libido in Pre and Postmenopausal Women Completed NCT02215434 Phase 2 Biolipid B2 (blanked/placebo);Testosterone, Transdermal, Behavior
45 Bupropion in Sexual Dysfunction Among Methadone Maintenance Treatment Men Recruiting NCT02593396 Phase 2 Bupropion hydrochloride sustained-release;placebo
46 Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD) Completed NCT01188603 Phase 1 flibanserin 100 mg dose every evening
47 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BP101 in Healthy Volunteers Active, not recruiting NCT03102489 Phase 1 BP101;Placebo
48 A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa® Terminated NCT01096329 Phase 1 Testosterone Spray 5% and 1%;Intrinsa® Patch and Testosterone Spray 5%;Intrinsa® Patch and Testosterone Spray 1%
49 Dehydroepiandrosterone (DHEA) Treatment in Women and Men Experiencing Hypoactive Sexual Desire Disorder Unknown status NCT00916396 Not Applicable Dehydroepiandrosterone;placebo
50 Prevalence of Metabolic Syndrome in Postmenopause Woman With Hypoactive Sexual Desire Disorder Completed NCT02430987

Search NIH Clinical Center for Hypoactive Sexual Desire Disorder

Cochrane evidence based reviews: sexual dysfunctions, psychological

Genetic Tests for Hypoactive Sexual Desire Disorder

Anatomical Context for Hypoactive Sexual Desire Disorder

MalaCards organs/tissues related to Hypoactive Sexual Desire Disorder:

41
Brain, Liver, Prostate, Testes, Ovary, Breast

Publications for Hypoactive Sexual Desire Disorder

Articles related to Hypoactive Sexual Desire Disorder:

(show top 50) (show all 192)
# Title Authors Year
1
Treatments for Hypoactive Sexual Desire Disorder (HSDD) and the Pursuit of Sexual Health for Women amidst Inglorious Rhetoric. ( 29914753 )
2018
2
Managing the Hypoactive Sexual Desire Disorder in Women. ( 29545004 )
2018
3
Re: Men's Sexual Response to Female Partner's Intranasal Oxytocin Administration for Hypoactive Sexual Desire Disorder: An Open Prospective Cohort Study. ( 29310164 )
2018
4
The International Society for the Study of Women's Sexual Health Process of Care for Management of Hypoactive Sexual Desire Disorder in Women. ( 29545008 )
2018
5
Evaluation and Management of Hypoactive Sexual Desire Disorder. ( 29523488 )
2018
6
Flibanserin for Hypoactive Sexual Desire Disorder: An Open-Label Safety Study. ( 29502984 )
2018
7
Ignorance Is Not Bliss: If We Don't Understand Hypoactive Sexual Desire Disorder, How Can Flibanserin Treat It? Commentary. ( 29396022 )
2018
8
Assessment of Sexual Desire for Clinical Trials of Women With Hypoactive Sexual Desire Disorder: Measures, Desire-Related Behavior, and Assessment of Clinical Significance. ( 29371145 )
2018
9
Flibanserin for hypoactive sexual desire disorder in premenopausal women. ( 29846316 )
2018
10
The characteristics of hypoactive sexual desire disorder in Korean women who visited a community-based gynaecology hospital for sexual dysfunction. ( 29433404 )
2018
11
Has flibanserin revolutionized the treatment of hypoactive sexual desire disorder or is there still room for more effective therapeutics? ( 29488405 )
2018
12
Transdermal Testosterone in Female Hypoactive Sexual Desire Disorder: A Rapid Qualitative Systematic Review Using Grading of Recommendations Assessment, Development and Evaluation. ( 29868302 )
2018
13
Flibanserin: A controversial drug for female hypoactive sexual desire disorder. ( 30416308 )
2018
14
Clinical management of hypoactive sexual desire disorder. ( 30422931 )
2018
15
Using the health belief model to predict those seeking treatment for Hypoactive Sexual Desire Disorder among premenopausal women. ( 30545528 )
2018
16
Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review. ( 27916394 )
2017
17
Metacognitive Therapy Trial for Hypoactive Sexual Desire Disorder Breaks the Mold. ( 29198515 )
2017
18
A Practical Approach to Managing Hypoactive Sexual Desire Disorder in Women with Diabetes. ( 28918588 )
2017
19
Efficacy of metacognitive therapy for hypoactive sexual desire disorder among Iranian couples. ( 28337949 )
2017
20
Re: Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review. ( 29370613 )
2017
21
Men's sexual response to female partner's intranasal oxytocin administration for hypoactive sexual desire disorder: an open prospective cohort study. ( 28189292 )
2017
22
Re: Men's Sexual Response to Female Partner's Intranasal Oxytocin Administration for Hypoactive Sexual Desire Disorder: An Open Prospective Cohort Study. ( 29370616 )
2017
23
Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder: Results of the PLUMERIA Study. ( 28583342 )
2017
24
Neuroimaging of Female Sexual Desire and Hypoactive Sexual Desire Disorder. ( 28865901 )
2017
25
New developments in the treatment of hypoactive sexual desire disorder - a focus on Flibanserin. ( 28442935 )
2017
26
Effect of Flibanserin Treatment on Body Weight in Premenopausal and Postmenopausal Women with Hypoactive Sexual Desire Disorder: A Post Hoc Analysis. ( 28817365 )
2017
27
Efficacy of Tribulus Terrestris for the treatment of premenopausal women with hypoactive sexual desire disorder: a randomized double-blinded, placebo-controlled trial. ( 29172782 )
2017
28
Role of hormones in hypoactive sexual desire disorder and current treatment. ( 29278235 )
2017
29
Flibanserin for hypoactive sexual desire disorder: place in therapy. ( 28203348 )
2017
30
Women With Hypoactive Sexual Desire Disorder versus Sexual Interest/Arousal Disorder: An Empirical Test of Raising the Bar. ( 29095039 )
2017
31
Understanding the Role of Serotonin in Female Hypoactive Sexual Desire Disorder and Treatment Options. ( 29198512 )
2017
32
Flibanserin Efficacy and Safety in Premenopausal Women With Generalized Acquired Hypoactive Sexual Desire Disorder. ( 28666836 )
2017
33
Route to Benzimidazol-2-ones via Decarbonylative Ring Contraction of Quinoxalinediones: Application to the Synthesis of Flibanserin, A Drug for Treating Hypoactive Sexual Desire Disorder in Women and Marine Natural Product Hunanamycin Analogue. ( 30023739 )
2017
34
What Sexual Behaviors Relate to Decreased Sexual Desire in Women? A Review and Proposal for End Points in Treatment Trials for Hypoactive Sexual Desire Disorder. ( 28041924 )
2016
35
FDA Approval of Flibanserin--Treating Hypoactive Sexual Desire Disorder. ( 26649985 )
2016
36
Acupuncture in Premenopausal Women With Hypoactive Sexual Desire Disorder: A Prospective Cohort Pilot Study. ( 27033339 )
2016
37
Flibanserin: A Novel, Nonhormonal Agent for the Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women. ( 26873507 )
2016
38
Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women: A Systematic Review and Meta-analysis. ( 26927498 )
2016
39
Flibanserin Ineffective for Hypoactive Sexual Desire Disorder in Women. ( 27583427 )
2016
40
Flibanserin (Addyi) for Hypoactive Sexual Desire Disorder in Premenopausal Women. ( 27175717 )
2016
41
Hypoactive Sexual Desire Disorder: A Review of Epidemiology, Biopsychology, Diagnosis, and Treatment. ( 27872021 )
2016
42
Flibanserin for Treating Hypoactive Sexual Desire Disorder. ( 27152308 )
2016
43
Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis. ( 27916205 )
2016
44
Efficacy of Tribulus terrestris for the treatment of hypoactive sexual desire disorder in postmenopausal women: a randomized, double-blinded, placebo-controlled trial. ( 27760089 )
2016
45
Psychometric Properties of the Sexual Interest and Desire Inventory-Female for Diagnosis of Hypoactive Sexual Desire Disorder: The Persian Version. ( 28050188 )
2016
46
First Pharmacological Therapy for Hypoactive Sexual Desire Disorder in Premenopausal Women: Flibanserin. ( 26692273 )
2016
47
Systematic Review and Meta-analysis of Flibanserin's Effects and Adverse Events in Women with Hypoactive Sexual Desire Disorder. ( 27784209 )
2016
48
Re: Psychological Treatment Trials for Hypoactive Sexual Desire Disorder: A Sexual Medicine Critique and Perspective. ( 27186767 )
2016
49
Efficacy and Safety of Flibanserin in Women with Hypoactive Sexual Desire Disorder: A Systematic Review and Meta-Analysis. ( 26745616 )
2015
50
Editorial Comment on "Psychology Treatment Trials for Hypoactive Sexual Desire Disorder: A Sexual Medicine Critique and Perspective". ( 26632093 )
2015

Variations for Hypoactive Sexual Desire Disorder

Expression for Hypoactive Sexual Desire Disorder

Search GEO for disease gene expression data for Hypoactive Sexual Desire Disorder.

Pathways for Hypoactive Sexual Desire Disorder

Pathways related to Hypoactive Sexual Desire Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.22 HTR1A HTR2A
2 11.02 HTR1A HTR2A
3 10.07 HTR1A HTR2A

GO Terms for Hypoactive Sexual Desire Disorder

Biological processes related to Hypoactive Sexual Desire Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.26 HTR1A HTR2A
2 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.16 HTR1A HTR2A
3 behavior GO:0007610 8.96 HTR1A HTR2A
4 serotonin receptor signaling pathway GO:0007210 8.62 HTR1A HTR2A

Molecular functions related to Hypoactive Sexual Desire Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.32 CYP19A1 CYP4F3
2 monooxygenase activity GO:0004497 9.26 CYP19A1 CYP4F3
3 neurotransmitter receptor activity GO:0030594 9.16 HTR1A HTR2A
4 G protein-coupled serotonin receptor activity GO:0004993 8.96 HTR1A HTR2A
5 serotonin binding GO:0051378 8.62 HTR1A HTR2A

Sources for Hypoactive Sexual Desire Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....